Abstract
To compare 24 h ambulatory blood pressure and trough office blood pressure lowerings after 8 weeks of therapy with 75 mg irbesartan once a day, 150 mg irbesartan once a day , and 75 mg irbesartan twice a day versus placebo; and to assess safety and tolerability of irbesartan therapy. Multicenter, double-blind, randomized, placebo-controlled trial. Sixteen centers in Italy. Caucasian patients (n = 215) aged > or = 18 years with seated diastolic blood pressure 95-110 mmHg and ambulatory diastolic blood pressure (ADBP) > or = 85 mmHg. Mean 24 h ADBP after 8 weeks of irbesartan therapy. Mean changes (value before treatment minus value after treatment) in ADBP for placebo, 75 mg irbesartan once a day, 150 mg irbesartan once a day, and 75 mg irbesartan twice a day were -0.2, -5.4, -7.2, and -7.2 mmHg, respectively; respective changes in ambulatory systolic blood pressure were +1.6, -8.3, -10.5, and -9.7 mmHg. All irbesartan regimens reduced trough office seated diastolic blood pressure and seated systolic blood pressure after 2 and 8 weeks of treatment (all P < 0.01, versus placebo except for seated systolic blood pressure in patients in the 75 mg irbesartan once a day group). Trough: peak ratios were > or = 55% with 150 mg irbesarta...Continue Reading
References
Dec 1, 1992·Journal of Hypertension·G ManciaE Mutti
Dec 1, 1991·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·E Thaulow, J E Erikssen
Feb 1, 1990·American Journal of Hypertension·M Rose, F G McMahon
Mar 1, 1995·American Journal of Hypertension·G ManciaA Zanchetti
Jan 1, 1995·Hypertension·A H van den MeirackerA J Man In 't Veld
Jul 1, 1994·American Journal of Hypertension·A Zanchetti
Jan 1, 1994·Journal of Hypertension·S Madhavan, M H Alderman
Oct 1, 1995·Journal of Hypertension·S OmboniG Mancia
Jul 1, 1996·Journal of Cardiovascular Pharmacology·M McIntyreJ L Reid
Citations
Oct 31, 2008·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yuhei KawanoKaoru Yoshinaga
Dec 18, 2014·The Annals of Pharmacotherapy·Paul M StrangesAmie D Brooks
Jun 11, 1998·Hypertension·R A ReevesH Pouleur
Feb 15, 2001·Circulation·M Burnier
Apr 13, 2004·Journal of Hypertension·Giuseppe Mancia, Gianfranco Parati
Mar 24, 2006·Journal of Endocrinological Investigation·S ZacharievaE Nachev
Apr 13, 2001·Journal of Cardiovascular Pharmacology·J RibsteinA Mimran
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Bernard Waeber, Michel Burnier
Oct 10, 2008·The Cochrane Database of Systematic Reviews·Balraj S HeranJames M Wright
Feb 24, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Claudio BorghiArrigo F G Cicero
Jun 6, 2002·Blood Pressure Monitoring·Giuseppe ManciaBarry Silvert
Jun 8, 2012·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Claudio Borghi, Arrigo F G Cicero
Jun 15, 2007·Journal of Hypertension·Maria Jose FabiaJosep Redon
Sep 17, 2013·Heart·James P HowardDarrel P Francis
Dec 19, 2002·Blood Pressure Monitoring·Thomas G PickeringAmy R Schwartz
Jun 21, 2001·The Journal of Clinical Hypertension·D A Sica
Nov 26, 1999·Clinical and Experimental Hypertension : CHE·P HoweK Kassler-Taub
Dec 5, 2009·Blood Pressure. Supplement·Giray KabakciHilmi Ozkutlu
Jan 27, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Stefano TaddeiLorenzo Ghiadoni
Aug 9, 2003·Expert Opinion on Drug Safety·Neil Shusterman
Apr 28, 2009·International Journal of Clinical Practice·R M NixonH Falvey
Jul 5, 2005·Expert Opinion on Investigational Drugs·C I Johnston
Dec 4, 2020·PloS One·Catherine G DeringtonKaty E Trinkley